Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia

Ron L. H. Handels; Anders Wimo; Richard Dodel; Milica G. Kramberger; Pieter Jelle Visser; Jose Luis Molinuevo; Frans R. J. Verhey; Bengt Winblad

doi:10.3233/JAD-170324

Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia

Ron L. H. Handels^*, Anders Wimo, Richard Dodel, Milica G. Kramberger, Pieter Jelle Visser, Jose Luis Molinuevo, Frans R. J. Verhey, Bengt Winblad

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

51 Downloads (Pure)

Original language	English
Pages (from-to)	1477-1487
Number of pages	11
Journal	Journal of Alzheimer's Disease
Volume	60
Issue number	4
DOIs	https://doi.org/10.3233/JAD-170324
Publication status	Published - 7 Nov 2017

Keywords

Alzheimer's disease
cerebrospinal fluid
cost-utility
economic evaluation
mild cognitive impairment
prognosis
risk
ASSOCIATION WORKGROUPS
DIAGNOSTIC GUIDELINES
MODIFYING TREATMENT
NATIONAL INSTITUTE
RECOMMENDATIONS
CRITERIA
IMPACT

Access to Document

10.3233/JAD-170324

Full TextFinal published version, 688 KBLicence: Taverne

Cite this

Handels, Ron L. H. ; Wimo, Anders ; Dodel, Richard ; Kramberger, Milica G. ; Visser, Pieter Jelle ; Luis Molinuevo, Jose ; Verhey, Frans R. J. ; Winblad, Bengt. / Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia. In: Journal of Alzheimer's Disease. 2017 ; Vol. 60, No. 4. pp. 1477-1487.

@article{3807b665aa4340fcb94dd172cb2f8014,

title = "Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia",

keywords = "Alzheimer's disease, cerebrospinal fluid, cost-utility, economic evaluation, mild cognitive impairment, prognosis, risk, ASSOCIATION WORKGROUPS, DIAGNOSTIC GUIDELINES, MODIFYING TREATMENT, NATIONAL INSTITUTE, RECOMMENDATIONS, CRITERIA, IMPACT",

author = "Handels, {Ron L. H.} and Anders Wimo and Richard Dodel and Kramberger, {Milica G.} and Visser, {Pieter Jelle} and {Luis Molinuevo}, Jose and Verhey, {Frans R. J.} and Bengt Winblad",

year = "2017",

month = nov,

day = "7",

doi = "10.3233/JAD-170324",

language = "English",

volume = "60",

pages = "1477--1487",

journal = "Journal of Alzheimer's Disease",

issn = "1387-2877",

publisher = "IOS Press",

number = "4",

}

Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia. / Handels, Ron L. H.; Wimo, Anders; Dodel, Richard; Kramberger, Milica G.; Visser, Pieter Jelle; Luis Molinuevo, Jose; Verhey, Frans R. J.; Winblad, Bengt.

In: Journal of Alzheimer's Disease, Vol. 60, No. 4, 07.11.2017, p. 1477-1487.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia

AU - Handels, Ron L. H.

AU - Wimo, Anders

AU - Dodel, Richard

AU - Kramberger, Milica G.

AU - Visser, Pieter Jelle

AU - Luis Molinuevo, Jose

AU - Verhey, Frans R. J.

AU - Winblad, Bengt

PY - 2017/11/7

Y1 - 2017/11/7

KW - Alzheimer's disease

KW - cerebrospinal fluid

KW - cost-utility

KW - economic evaluation

KW - mild cognitive impairment

KW - prognosis

KW - risk

KW - ASSOCIATION WORKGROUPS

KW - DIAGNOSTIC GUIDELINES

KW - MODIFYING TREATMENT

KW - NATIONAL INSTITUTE

KW - RECOMMENDATIONS

KW - CRITERIA

KW - IMPACT

U2 - 10.3233/JAD-170324

DO - 10.3233/JAD-170324

M3 - Article

VL - 60

SP - 1477

EP - 1487

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 4

ER -